PL3470063T3 - Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy cftr - Google Patents
Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy cftrInfo
- Publication number
- PL3470063T3 PL3470063T3 PL18192504.1T PL18192504T PL3470063T3 PL 3470063 T3 PL3470063 T3 PL 3470063T3 PL 18192504 T PL18192504 T PL 18192504T PL 3470063 T3 PL3470063 T3 PL 3470063T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- pharmaceutical compositions
- mediated diseases
- cftr mediated
- cftr
- Prior art date
Links
- 101150029409 CFTR gene Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721622P | 2012-11-02 | 2012-11-02 | |
| US201261728328P | 2012-11-20 | 2012-11-20 | |
| US201361770668P | 2013-02-28 | 2013-02-28 | |
| US201361824005P | 2013-05-16 | 2013-05-16 | |
| US201361840668P | 2013-06-28 | 2013-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3470063T3 true PL3470063T3 (pl) | 2025-04-14 |
Family
ID=50628072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18192504.1T PL3470063T3 (pl) | 2012-11-02 | 2013-11-01 | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy cftr |
| PL13792149.0T PL2914248T5 (pl) | 2012-11-02 | 2013-11-01 | Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13792149.0T PL2914248T5 (pl) | 2012-11-02 | 2013-11-01 | Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20140163068A1 (pl) |
| EP (3) | EP2914248B2 (pl) |
| JP (4) | JP6302923B2 (pl) |
| KR (1) | KR102396897B1 (pl) |
| CN (2) | CN104869982A (pl) |
| AR (1) | AR093340A1 (pl) |
| AU (4) | AU2013337730B2 (pl) |
| BR (1) | BR112015009913B1 (pl) |
| CA (1) | CA2890106C (pl) |
| CL (1) | CL2015001148A1 (pl) |
| CY (1) | CY1121070T1 (pl) |
| DK (2) | DK2914248T4 (pl) |
| ES (2) | ES2694290T5 (pl) |
| FI (2) | FI3470063T3 (pl) |
| HR (2) | HRP20250100T1 (pl) |
| HU (2) | HUE070382T2 (pl) |
| IL (2) | IL283276B2 (pl) |
| LT (2) | LT3470063T (pl) |
| MX (2) | MX368353B (pl) |
| NZ (2) | NZ708474A (pl) |
| PL (2) | PL3470063T3 (pl) |
| PT (2) | PT3470063T (pl) |
| RS (2) | RS57831B2 (pl) |
| SG (3) | SG10201703452PA (pl) |
| SI (2) | SI2914248T2 (pl) |
| SM (2) | SMT202500078T1 (pl) |
| TR (1) | TR201815218T4 (pl) |
| TW (2) | TW201422253A (pl) |
| UA (2) | UA117464C2 (pl) |
| WO (1) | WO2014071122A1 (pl) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200602755B (en) | 2003-09-06 | 2007-06-27 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| NZ587549A (en) | 2004-06-24 | 2012-10-26 | Vertex Pharma | 6-Amino-indole derivatives and processes for their preparation |
| EP1912983B1 (en) | 2005-08-11 | 2011-06-08 | Vertex Pharmaceuticals, Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR101331768B1 (ko) | 2005-11-08 | 2013-11-22 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제 |
| CA2635581C (en) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| PL2674428T3 (pl) | 2006-04-07 | 2017-01-31 | Vertex Pharmaceuticals Incorporated | Modulatory transporterów z kasetą wiążącą ATP |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| CA2686838C (en) | 2007-05-09 | 2017-03-14 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| AU2008302598B2 (en) | 2007-08-24 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Isothiazolopyridinones useful for the treatment of (inter alia) Cystic Fibrosis |
| SI2578571T1 (sl) | 2007-11-16 | 2016-01-29 | Vertex Pharmaceuticals Incorporated | Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto |
| DK2639223T3 (en) | 2007-12-07 | 2017-06-19 | Vertex Pharma | Process for Preparation of Cycloalkylcarboxiamido-pyridine Benzoic Acids |
| HRP20170241T2 (hr) | 2007-12-07 | 2023-03-17 | Vertex Pharmaceuticals Incorporated | Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| NZ736561A (en) | 2008-02-28 | 2018-02-23 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| PL2408750T3 (pl) | 2009-03-20 | 2016-02-29 | Vertex Pharma | Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| DK3150198T3 (da) | 2010-04-07 | 2021-11-01 | Vertex Pharma | Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf |
| RS54783B1 (sr) | 2010-04-07 | 2016-10-31 | Vertex Pharma | Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline |
| CA2797118C (en) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| MX357328B (es) | 2011-11-08 | 2018-07-05 | Vertex Pharma | Moduladores de trasportadores de casete enlazante de atp. |
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| AU2013226076B2 (en) | 2012-02-27 | 2017-11-16 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| SMT202500078T1 (it) * | 2012-11-02 | 2025-03-12 | Vertex Pharma | Composizioni farmaceutiche per il trattamento di malattie mediate da cftr |
| US9303918B2 (en) * | 2013-03-15 | 2016-04-05 | Monosol Rx, Llc | Process for drying a wet film with control of loss on drying |
| WO2014176553A1 (en) * | 2013-04-26 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Correctors acting through msd1 of cftr protein |
| RU2718044C2 (ru) * | 2013-11-12 | 2020-03-30 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
| RS62140B1 (sr) | 2014-04-15 | 2021-08-31 | Vertex Pharma | Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze |
| IL313498A (en) | 2014-10-06 | 2024-08-01 | Vertex Pharma | Modulators of the cystic fibrosis transmembrane conductance regulator |
| KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
| HRP20211194T1 (hr) | 2014-11-18 | 2021-10-29 | Vertex Pharmaceuticals Inc. | Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti |
| MX2017014344A (es) | 2015-05-11 | 2018-04-11 | Abide Therapeutics Inc | Metodos para el tratamiento de la inflacion o el dolor neuropatico. |
| HK1258473A1 (zh) | 2015-09-25 | 2019-11-15 | Vertex Pharmaceuticals (Europe) Limited | 氘代cftr增效剂 |
| WO2017151725A1 (en) * | 2016-03-03 | 2017-09-08 | Nivalis Therapeutics, Inc. | Formulations of an s-nitrosoglutathione reductase inhibitor |
| EP3436446B1 (en) | 2016-03-31 | 2023-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US10206915B2 (en) | 2016-04-25 | 2019-02-19 | Druggability Technologies Ip Holdco Limited | Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| HUP1600271A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei |
| HUP1600270A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei |
| US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
| HUP1600269A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei |
| HRP20211683T1 (hr) | 2016-09-30 | 2022-03-04 | Vertex Pharmaceuticals Incorporated | Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora |
| JOP20190108B1 (ar) * | 2016-11-16 | 2023-09-17 | H Lundbeck As | تركيبات صيدلانية |
| HUE064559T2 (hu) | 2016-11-16 | 2024-03-28 | H Lundbeck As | MAGL inhibitor kristályos formája |
| MX2021013639A (es) | 2016-12-09 | 2022-09-30 | Vertex Pharma | Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística. |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| IL305169B2 (en) | 2017-12-01 | 2025-07-01 | Vertex Pharma | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| LT3752510T (lt) | 2018-02-15 | 2023-04-11 | Vertex Pharmaceuticals Incorporated | Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas |
| WO2019195739A1 (en) | 2018-04-05 | 2019-10-10 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| RS64192B9 (sr) | 2018-11-14 | 2025-10-31 | Vertex Pharma | Metode lečenja cistične fibroze |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| MX2022001827A (es) | 2019-08-14 | 2022-06-09 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de la fibrosis quistica. |
| US11584761B2 (en) | 2019-08-14 | 2023-02-21 | Vertex Pharmaceuticals Incorporated | Process of making CFTR modulators |
| EP4013760A1 (en) | 2019-08-14 | 2022-06-22 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| US11904006B2 (en) | 2019-12-11 | 2024-02-20 | University Of Iowa Research Foundation | Poly(diaminosulfide) particle-based vaccine |
| KR20230004622A (ko) | 2020-04-21 | 2023-01-06 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제의 합성 |
| WO2022194399A1 (en) | 2020-07-13 | 2022-09-22 | Idorsia Pharmaceuticals Ltd | Macrocycles as cftr modulators |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US20230373974A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225737A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076626A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230373935A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225764A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225761A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230382924A1 (en) | 2020-10-07 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225765A2 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2021356651A1 (en) | 2020-10-07 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US20240100183A1 (en) * | 2020-12-11 | 2024-03-28 | University Of Iowa Research Foundation | Compositions comprising molecules for cystic fibrosis treatment |
| CA3211232A1 (en) * | 2021-03-09 | 2022-09-15 | Hemant Bhagwat NARKHEDE | Oral film of cftr modulator(s) |
| IL314449A (en) | 2022-02-03 | 2024-09-01 | Vertex Pharma | Methods of treatment for cystic fibrosis |
| CN118974059A (zh) | 2022-02-08 | 2024-11-15 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控因子的调节剂 |
| GEAP202516620A (en) | 2022-04-06 | 2025-04-10 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN119947720A (zh) | 2022-05-16 | 2025-05-06 | 弗特克斯药品有限公司 | 治疗囊性纤维化的方法 |
| CN119894906A (zh) | 2022-09-15 | 2025-04-25 | 爱杜西亚药品有限公司 | 大环cftr调节剂 |
| CN119907667A (zh) | 2022-09-15 | 2025-04-29 | 爱杜西亚药品有限公司 | 大环cftr调节剂与cftr校正剂和/或cftr增效剂的组合 |
| TW202421636A (zh) | 2022-09-15 | 2024-06-01 | 瑞士商愛杜西亞製藥有限公司 | (3S,7S,10R,13R)-13-苄基-20-氟-7-異丁基-N-(2-(3-甲氧基-1,2,4-㗁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四側氧基-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氫-[1]㗁[4,7,10,14]四氮雜環十七烷并[16,17-f]喹啉-3-甲醯胺的晶型 |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| CA2500498C (en) | 2002-09-30 | 2012-08-21 | The Regents Of The University Of California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| WO2004080972A1 (en) | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
| US6992096B2 (en) | 2003-04-11 | 2006-01-31 | Ptc Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| WO2004110352A2 (en) | 2003-05-16 | 2004-12-23 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| CA2465565A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US7598412B2 (en) | 2003-10-08 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| JP4869072B2 (ja) | 2003-11-14 | 2012-02-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール |
| US7414037B2 (en) | 2004-03-30 | 2008-08-19 | The Regents Of The University Of California | Hydrazide-containing CFTR inhibitor compounds and uses thereof |
| AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| NZ587549A (en) | 2004-06-24 | 2012-10-26 | Vertex Pharma | 6-Amino-indole derivatives and processes for their preparation |
| WO2006044456A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| EP1865949B1 (en) | 2005-03-11 | 2012-11-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| JP2008538107A (ja) | 2005-03-18 | 2008-10-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 変異型ｃｆｔｒプロセシングの修正において活性を有する化合物及びその用途 |
| PT1874306E (pt) | 2005-04-08 | 2012-10-11 | Ptc Therapeutics Inc | Composições de um 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações sem sentido (ou nonsense) |
| ATE533749T1 (de) | 2005-05-24 | 2011-12-15 | Vertex Pharma | Modulatoren von atp-bindenden kassettentransportern |
| KR20080064971A (ko) | 2005-10-06 | 2008-07-10 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｐ-결합 카세트 전달체의 조절자 |
| KR101331768B1 (ko) | 2005-11-08 | 2013-11-22 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제 |
| ES2361595T3 (es) | 2007-05-07 | 2011-06-20 | Novartis Ag | Compuestos orgánicos. |
| MX2010002974A (es) * | 2007-09-14 | 2010-07-29 | Vertex Pharma | Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida. |
| HRP20170241T2 (hr) * | 2007-12-07 | 2023-03-17 | Vertex Pharmaceuticals Incorporated | Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline |
| KR101578235B1 (ko) | 2007-12-10 | 2015-12-16 | 노파르티스 아게 | 유기 화합물 |
| AU2009256645A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers |
| ES2660143T3 (es) * | 2008-08-13 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Composición farmacéutica de N-[2,4-Bis(1,1-dimetiletilo)-5-hidroxifenilo]-1,4-dihidro-4-oxoquinolina-3carboxamida y administración de la misma |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US8716338B2 (en) * | 2008-09-29 | 2014-05-06 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| CN102803234A (zh) * | 2009-06-02 | 2012-11-28 | 霓坎制药有限责任公司 | 用于治疗疾病的人甲酰基肽受体的拮抗作用 |
| JP2011034380A (ja) * | 2009-08-03 | 2011-02-17 | Nitto Denko Corp | タッチパネルおよびタッチパネル付表示装置 |
| WO2011028740A1 (en) | 2009-09-03 | 2011-03-10 | Glaxo Group Limited | ENaC BLOCKERS |
| WO2011079087A1 (en) | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| DK3150198T3 (da) † | 2010-04-07 | 2021-11-01 | Vertex Pharma | Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf |
| NZ603042A (en) * | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| US10105356B2 (en) * | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
| SG10201606135TA (en) * | 2012-01-25 | 2016-09-29 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| SMT202500078T1 (it) * | 2012-11-02 | 2025-03-12 | Vertex Pharma | Composizioni farmaceutiche per il trattamento di malattie mediate da cftr |
| RU2718044C2 (ru) * | 2013-11-12 | 2020-03-30 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
-
2013
- 2013-11-01 SM SM20250078T patent/SMT202500078T1/it unknown
- 2013-11-01 IL IL283276A patent/IL283276B2/en unknown
- 2013-11-01 CA CA2890106A patent/CA2890106C/en active Active
- 2013-11-01 EP EP13792149.0A patent/EP2914248B2/en active Active
- 2013-11-01 KR KR1020157014464A patent/KR102396897B1/ko active Active
- 2013-11-01 DK DK13792149.0T patent/DK2914248T4/da active
- 2013-11-01 BR BR112015009913-0A patent/BR112015009913B1/pt active IP Right Grant
- 2013-11-01 SG SG10201703452PA patent/SG10201703452PA/en unknown
- 2013-11-01 PL PL18192504.1T patent/PL3470063T3/pl unknown
- 2013-11-01 FI FIEP18192504.1T patent/FI3470063T3/fi active
- 2013-11-01 CN CN201380066317.9A patent/CN104869982A/zh active Pending
- 2013-11-01 TR TR2018/15218T patent/TR201815218T4/tr unknown
- 2013-11-01 AU AU2013337730A patent/AU2013337730B2/en active Active
- 2013-11-01 HU HUE18192504A patent/HUE070382T2/hu unknown
- 2013-11-01 RS RS20181318A patent/RS57831B2/sr unknown
- 2013-11-01 CN CN202010527346.2A patent/CN111671751A/zh active Pending
- 2013-11-01 HU HUE13792149A patent/HUE039864T2/hu unknown
- 2013-11-01 MX MX2015005559A patent/MX368353B/es active IP Right Grant
- 2013-11-01 SI SI201331163T patent/SI2914248T2/sl unknown
- 2013-11-01 HR HRP20250100TT patent/HRP20250100T1/hr unknown
- 2013-11-01 TW TW102139864A patent/TW201422253A/zh unknown
- 2013-11-01 PT PT181925041T patent/PT3470063T/pt unknown
- 2013-11-01 EP EP24223819.4A patent/EP4556008A3/en active Pending
- 2013-11-01 SI SI201332096T patent/SI3470063T1/sl unknown
- 2013-11-01 PT PT13792149T patent/PT2914248T/pt unknown
- 2013-11-01 SM SM20180590T patent/SMT201800590T1/it unknown
- 2013-11-01 SG SG10201913581UA patent/SG10201913581UA/en unknown
- 2013-11-01 DK DK18192504.1T patent/DK3470063T3/da active
- 2013-11-01 TW TW107117580A patent/TWI736768B/zh active
- 2013-11-01 US US14/069,571 patent/US20140163068A1/en not_active Abandoned
- 2013-11-01 UA UAA201505319A patent/UA117464C2/uk unknown
- 2013-11-01 EP EP18192504.1A patent/EP3470063B1/en active Active
- 2013-11-01 FI FIEP13792149.0T patent/FI2914248T4/fi active
- 2013-11-01 UA UAA201803746A patent/UA123631C2/uk unknown
- 2013-11-01 RS RS20250226A patent/RS66596B1/sr unknown
- 2013-11-01 ES ES13792149T patent/ES2694290T5/es active Active
- 2013-11-01 SG SG11201503365YA patent/SG11201503365YA/en unknown
- 2013-11-01 WO PCT/US2013/067952 patent/WO2014071122A1/en not_active Ceased
- 2013-11-01 JP JP2015540796A patent/JP6302923B2/ja active Active
- 2013-11-01 NZ NZ708474A patent/NZ708474A/en unknown
- 2013-11-01 ES ES18192504T patent/ES3009747T3/es active Active
- 2013-11-01 PL PL13792149.0T patent/PL2914248T5/pl unknown
- 2013-11-01 LT LTEP18192504.1T patent/LT3470063T/lt unknown
- 2013-11-01 LT LTEP13792149.0T patent/LT2914248T/lt unknown
- 2013-11-01 HR HRP20181740TT patent/HRP20181740T4/hr unknown
- 2013-11-01 NZ NZ745659A patent/NZ745659A/en unknown
- 2013-11-04 AR ARP130104018A patent/AR093340A1/es not_active Application Discontinuation
-
2015
- 2015-04-30 CL CL2015001148A patent/CL2015001148A1/es unknown
- 2015-04-30 MX MX2019011662A patent/MX2019011662A/es unknown
- 2015-04-30 IL IL238551A patent/IL238551B/en active IP Right Grant
-
2016
- 2016-05-11 US US15/152,092 patent/US20160324846A1/en not_active Abandoned
-
2018
- 2018-03-05 JP JP2018038741A patent/JP2018090626A/ja not_active Withdrawn
- 2018-09-14 AU AU2018229528A patent/AU2018229528A1/en not_active Abandoned
- 2018-11-30 CY CY20181101277T patent/CY1121070T1/el unknown
-
2019
- 2019-05-07 JP JP2019087813A patent/JP7003085B2/ja active Active
- 2019-12-20 US US16/722,290 patent/US20200338063A1/en not_active Abandoned
-
2020
- 2020-06-17 AU AU2020204037A patent/AU2020204037B2/en active Active
-
2021
- 2021-12-28 JP JP2021214209A patent/JP2022034069A/ja active Pending
-
2022
- 2022-12-30 US US18/091,472 patent/US20230364073A1/en active Pending
-
2024
- 2024-01-16 AU AU2024200273A patent/AU2024200273A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277470A (en) | Manufacturing method for pharmaceutical preparations for the treatment of diseases caused by CFTR | |
| SG11201503365YA (en) | Pharmaceutical compositions for the treatment of cftr mediated diseases | |
| IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
| PT2818482T (pt) | Composição farmacêutica para o tratamento de cancro | |
| PL2824114T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| LT2925757T (lt) | Junginiai ir kompozicijos, skirti parazitinių ligų gydymui | |
| IL234831B (en) | Medical preparations for combined treatment | |
| IL235058A0 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| LT2814473T (lt) | Farmacinės kompozicijos, skirtos derinių terapijai | |
| HUE037176T2 (hu) | Olaj-alapú gyógyszerészeti készítmény gasztrointesztinális betegségek kezelésére | |
| PT2812351T (pt) | Composição farmacêutica para o tratamento de esclerose múltipla | |
| HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds | |
| HUE043019T2 (hu) | Gyógyszerészeti készítmények kombinációs terápia céljára |